CD4/CD8 Ratio Recovered as a Predictor of Decreased Liver Damage in Adults Infected With HIV: 16-Year Observational Cohort Study

• DOI: 10.2196/45818
• Publication Date: 2023-10-17T04:07:06Z
• Authors: Bingyu Liang; Rujing Sun; Yanyan Liao; Aidan Nong; Jinfeng He; Fengxiang Qin; Yanyun Ou; Jianhua Che; Zhenxian Wu; Yuan Yang; Jiao Qin; Jie Cai; Lijuan Bao; Li Ye; Hao Liang
• Keywords: CD4-CD8 Ratio; Rate ratio

Background: As the life expectancy of individuals infected with HIV continues to increase, vigilant monitoring non-AIDS-related events becomes imperative, particularly those pertaining liver diseases.In comparison general population, patients experience a higher frequency liver-related deaths.The CD4/CD8 ratio is emerging as potential biomarker for events.However, few existing studies have been specially designed explore relationship between and specific types events, notably damage.Objective: This study aimed investigate association development damage in sizable cohort receiving antiretroviral treatment (ART).Additionally, sought assess effectiveness 3 drugs recovering reducing occurrence this population. Methods:We conducted an observational among adults ART from 2004 2020 Guangxi, China.Propensity score matching, multivariable Cox proportional hazard, Fine-Gray competing risk regression models were used determine recovered damage. Results:The incidence was 20.12% 2440 eligible during median follow-up period 4 person-years.Patients whose did not recover 1.0 exhibited compared (adjusted hazard 7.90, 95% CI 4.39-14.21;P<.001; subdistribution 6.80, 3.83-12.11;P<.001), findings consistent propensity matching analysis 6.94, 3.41-14.12;P<.001; 5.67, 2.74-11.73;P<.001).The Efavirenz-based regimen shortest time recovery (median 71, IQR 49-88 months) demonstrated lower prevalence (4.18/100 person-years).Conclusions: Recovery associated decreased ART, adding evidence considering marker identifying at diseases.An efavirenz-based emerged recommended choice mitigating